$1,318.00
This Market Spotlight report covers the Hepatitis B market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Hepatitis B market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
10 TREATMENT
10 Nucleos(t)ide analogs
10 Interferons
11 EPIDEMIOLOGY
11 Epidemiology – global and regional
17 Epidemiology – country-specific
23 MARKETED DRUGS
26 PIPELINE DRUGS
33 RECENT EVENTS AND ANALYST OPINION
33 EYP001 for Hepatitis B (July 30, 2021)
34 Vebicorvir for Hepatitis B (November 5, 2020)
37 KEY UPCOMING EVENTS
38 KEY REGULATORY EVENTS
38 Positive CHMP Opinion For VBI Vaccines’ PreHevbri
39 PROBABILITY OF SUCCESS
40 LICENSING AND ASSET ACQUISITION DEALS
40 Janssen Terminates Part Of 2015 Collaboration With Bavarian Nordic
40 Shionogi, NEC Team Up On Development Of Novel Hep B Vaccine
40 Qilu Ties Up With Arbutus For RNAi Therapy
40 Antios Acquires IP For Hep B Therapy From IRBM
40 Alphamab Expands Deal With Ascletis For Worldwide Rights To Antiviral
42 REVENUE OPPORTUNITY
44 CLINICAL TRIAL LANDSCAPE
45 Sponsors by status
46 Sponsors by phase
47 Recent events
49 BIBLIOGRAPHY
50 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in prevalent cases of hepatitis B, 2021–30
26 Figure 2: Overview of pipeline drugs for hepatitis B in the US
26 Figure 3: Pipeline drugs for hepatitis B, by company
27 Figure 4: Pipeline drugs for hepatitis B, by drug type
27 Figure 5: Pipeline drugs for hepatitis B, by classification
36 Figure 6: Vebicorvir for Hepatitis B (November 5, 2020): Phase II – Study 211
37 Figure 7: Key upcoming events in hepatitis B
39 Figure 8: Probability of success in the antiviral pipeline
44 Figure 9: Clinical trials in hepatitis B
44 Figure 10: Top 10 drugs for clinical trials in hepatitis B
45 Figure 11: Top 10 companies for clinical trials in hepatitis B
45 Figure 12: Trial locations in hepatitis B
46 Figure 13: Hepatitis B trials status
47 Figure 14: Hepatitis B trials sponsors, by phase
LIST OF TABLES
12 Table 1: Prevalent cases of hepatitis B, by region, 2021–30
14 Table 2: Diagnosed prevalent cases of hepatitis B, by region, 2021
16 Table 3: Treatment-eligible and treated prevalent cases of hepatitis B, by region, 2021
18 Table 4: Prevalent cases of hepatitis B, by country, 2021–30
19 Table 5: Diagnosed prevalent cases of hepatitis B, by country, 2021
21 Table 6: Treatment-eligible and treated prevalent cases of hepatitis B, by country, 2021
24 Table 7: Marketed drugs for hepatitis B
28 Table 8: Pipeline drugs for hepatitis B in the US
33 Table 9: EYP001 for Hepatitis B (July 30, 2021)
35 Table 10: Vebicorvir for Hepatitis B (November 5, 2020)
42 Table 11: Historical global sales, by drug ($m), 2017–21
43 Table 12: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!